---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Pirtobrutinib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/pirtobrutinib
version: v1
---

# Pirtobrutinib - NCI

# Pirtobrutinib

Placeholder slot

(PEER-toh-BROO-tih-nib)

This page contains brief information about pirtobrutinib
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Jaypirca

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801&audience=consumer)

## Use in Cancer

Pirtobrutinib
is approved to treat:

- **[Chronic lymphocytic leukemia or small lymphocytic lymphoma](/Common/PopUps/popDefinition.aspx?id=641290&version=Patient&language=English).** It is used in adults who have received at least two types of therapy, including a [BTK inhibitor](/Common/PopUps/popDefinition.aspx?id=811784&version=Patient&language=English) and a [BCL2](/Common/PopUps/popDefinition.aspx?id=613897&version=Patient&language=English) [inhibitor](/Common/PopUps/popDefinition.aspx?id=491505&version=Patient&language=English).
- **[Mantle cell lymphoma](/Common/PopUps/popDefinition.aspx?id=445048&version=Patient&language=English).** It is used in adults whose cancer has come back or has not gotten better after at least two types of [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English), including a BTK inhibitor.

Pirtobrutinib is approved under FDAâ€™s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that it provides a clinical benefit in these patients.

Pirtobrutinib
is also being studied in the treatment of other types of
cancer.

## More About Pirtobrutinib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/797383) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Pirtobrutinib](https://medlineplus.gov/druginfo/meds/a623012.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Pirtobrutinib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C158617) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
